Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;77(4):889-906.
doi: 10.1007/s43440-025-00749-y. Epub 2025 Jun 13.

Inflammatory lung diseases: a clinical and scientific review of the latest advances and challenges

Affiliations
Review

Inflammatory lung diseases: a clinical and scientific review of the latest advances and challenges

Ahmed A Katamesh et al. Pharmacol Rep. 2025 Aug.

Abstract

Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, pulmonary sarcoidosis, and interstitial lung diseases (ILDs), represent a significant cause of morbidity and mortality globally. These conditions are characterized by chronic inflammation and tissue damage, leading to substantial respiratory compromise and impairing quality of life. This review aims to provide a comprehensive overview of pathogenesis, clinical features, and diagnostic approaches for inflammatory lung diseases, emphasizing their shared and distinct characteristics. The review synthesizes current literature on the genetic predisposition, environmental exposures, and immune responses involved in the development and progression of inflammatory lung diseases. It also examines the classification and staging of these conditions to highlight the importance of accurate diagnosis and effective management. Key findings include the complex interplay of numerous factors that contribute to disease development and progression, as well as an analysis of classification and staging systems that support clinical practice. By elucidating the underlying mechanisms and clinical features of inflammatory lung diseases, this review aims to inform the development of novel therapeutic strategies and enhance patient outcomes.

Not applicable.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: No human or animal studies have been performed in the work toward the completion of this article. Therefore, no ethical approvals are required. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Similar articles

References

    1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung Cancer. Annals Global Health. 2019;85(1):8.
    1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Annals Am Thorac Soc. 2014;11(3):404–6.
    1. Zar HJ, Ferkol TW. The global burden of respiratory disease—impact on child health. Wiley Online Library; 2014. pp. 430–4.
    1. Shukla SD, Swaroop Vanka K, Chavelier A, Shastri MD, Tambuwala MM, Bakshi HA et al. Chap. 1 - Chronic respiratory diseases: An introduction and need for novel drug delivery approaches, in Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems, K. Dua, Editors. 2020, Academic Press. pp. 1–31.
    1. Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K et al. Recent advances in immunotherapies against infectious diseases. Immunotherapy Adv. 2020;1(1).